---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-018524"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:34:24.662992+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aptose raises ~$13M in public offering and Hanmi PIPE for tuspetinib development

## Summary
- Underwriting agreement for 4,912,280 common shares and warrants at $1.71 per unit; net proceeds ~$9.0M.
- Over-allotment option fully exercised for additional 736,842 shares/warrants.
- Hanmi invests $4M for 2,105,263 common shares and 2,339,181 warrants at $1.90 per combined set.
- Hanmi will hold ~19.99% of outstanding shares post-offering; amended investor rights agreement.
- Proceeds from offering and PIPE to fund tuspetinib development.

## SEC filing metadata
- accession: 0001193125-24-018524
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/0001193125-24-018524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/d742545d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-018524
- JSON: https://secwatch.observer/filing/0001193125-24-018524.json
- Plain text: https://secwatch.observer/filing/0001193125-24-018524.txt

## Key facts
- Material Agreements
  Aptose Biosciences Inc. entered into Funding Satisfaction Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2024-01-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Hanmi Pharmaceutical Co., Ltd.
  - Effective: 2024-01-25
  source text: In connection with the completion of the Hanmi Investment, Aptose and Hanmi have entered into an agreement (the “ Funding Satisfaction Agreement ”), dated January 25, 2024, that provides that upon completion of the Hanmi Investment, Hanmi’s obligation to fund the second tranche of its investment pursuant to the subscription agreement entered by Aptose and Hanmi on September 6, 2023, will be deemed to be satisfied.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/0001193125-24-018524-index.htm
- Material Agreements
  Aptose Biosciences Inc. amended Amended and Restated Investor's Rights Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2024-01-25).
  - Action: amendment
  - Counterparty: Hanmi Pharmaceutical Co., Ltd.
  - Effective: 2024-01-25
  source text: Investor Rights Agreement In connection with the Hanmi Investment, Aptose and Hanmi entered into an Amended and Restated Investor’s Rights Agreement (the “ Investor Rights Agreement ”), which amends and restates the Investor’s Rights Agreement entered by the parties on September 6, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/0001193125-24-018524-index.htm
- Material Agreements
  Aptose Biosciences Inc. entered into Underwriting Agreement with Newbridge Securities Corporation, as Underwriter valued at approximately $9.0 million in net proceeds from the Offering (effective 2024-01-25).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Newbridge Securities Corporation, as Underwriter
  - Value: approximately $9.0 million in net proceeds from the Offering
  - Effective: 2024-01-25
  source text: Underwriting Agreement On January 25, 2024, Aptose Biosciences Inc. (“ Aptose ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Newbridge Securities Corporation, as Underwriter, pursuant to which Aptose agreed to issue and sell 4,912,280 common shares and 4,912,280 warrants to acquire common shares (the “ Warrants ”) at a combined public offering price of $1.71 per common share and Warrant (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/0001193125-24-018524-index.htm
- Material Agreements
  Aptose Biosciences Inc. entered into Subscription Agreement with Hanmi Pharmaceutical Co., Ltd. valued at $4.0 million (effective 2024-01-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Hanmi Pharmaceutical Co., Ltd.
  - Value: $4.0 million
  - Effective: 2024-01-25
  source text: Subscription Agreement On January 25, 2024, Aptose entered into a subscription agreement (the “ Subscription Agreement ”) with Hanmi Pharmaceutical Co., Ltd., a corporation formed under the laws of the Republic of Korea, pursuant to which Aptose agreed to sell and issue to Hanmi and Hanmi agreed to purchase from Aptose $4.0 million of Aptose’s common shares and warrants to purchase common shares (the “ Hanmi Investment ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000119312524018524/0001193125-24-018524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.